• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    4/28/25 12:49:50 PM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email
    6-K 1 a4743g.htm HOLDING(S) IN COMPANY a4743g
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16 under the
    Securities Exchange Act of 1934
     
    April 28, 2025
     
    Commission File Number 001-14978
     
    SMITH & NEPHEW plc
    (Registrant’s name)
     
    Building 5, Croxley Park, Hatters Lane
    Watford, England, WD18 8YE
     (Address of principal executive office)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F a         Form 40-F __
     
     
     
    TR-1: Standard form for notification of major holdings
     
    1. Issuer Details
     
    ISIN
    GB0009223206
     
    Issuer Name
    SMITH & NEPHEW PLC
     
    UK or Non-UK Issuer
    UK
     
    2. Reason for Notification
     
    An acquisition or disposal of voting rights
     
    3. Details of person subject to the notification obligation
     
    Name
    Norges Bank
     
    City of registered office (if applicable)
    Oslo
     
    Country of registered office (if applicable)
    Norway
     
    4. Details of the shareholder
     
    Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
     
     
    City of registered office (if applicable)
     
     
    Country of registered office (if applicable)
     
     
    5. Date on which the threshold was crossed or reached
     
    25-Apr-2025
     
    6. Date on which Issuer notified
     
    28-Apr-2025
     
    7. Total positions of person(s) subject to the notification obligation
     
     
    % of voting rights attached to shares (total of 8.A)
    % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
    Total of both in % (8.A + 8.B)
    Total number of voting rights held in issuer
    Resulting situation on the date on which threshold was crossed or reached
     
    2.394680
     
    0.000000
     
    2.394680
     
    20975716
     
    Position of previous notification (if applicable)
     
    3.029740
     
    0.024260
     
    3.054000
     
     
     
    8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
     
    8A. Voting rights attached to shares
     
    Class/Type of shares ISIN code(if possible)
    Number of direct voting rights (DTR5.1)
    Number of indirect voting rights (DTR5.2.1)
    % of direct voting rights (DTR5.1)
    % of indirect voting rights (DTR5.2.1)
    GB0009223206
     
    20975716
     
     
    2.394680
     
     
    Sub Total 8.A
    20975716
     
    2.394680%
     
     
    8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
     
    Type of financial instrument
     
    Expiration date
     
    Exercise/conversion period
     
    Number of voting rights that may be acquired if the instrument is exercised/converted
     
    % of voting rights
     
     
     
     
     
     
     
    Sub Total 8.B1
     
     
     
     
     
    8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
     
    Type of financial instrument
     
    Expiration date
     
    Exercise/conversion period
     
    Physical or cash settlement
     
    Number of voting rights
     
    % of voting rights
     
     
     
     
     
     
     
     
    Sub Total 8.B2
     
     
     
     
     
    9. Information in relation to the person subject to the notification obligation
     
    1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
     
    Ultimate controlling person
    Name of controlled undertaking
    % of voting rights if it equals or is higher than the notifiable threshold
    % of voting rights through financial instruments if it equals or is higher than the notifiable threshold
    Total of both if it equals or is higher than the notifiable threshold
     
     
     
     
     
     
     
    10. In case of proxy voting
     
    Name of the proxy holder
     
     
     
    The number and % of voting rights held
     
     
     
    The date until which the voting rights will be held
     
     
     
    11. Additional Information
     
     
     
    12. Date of Completion
     
    28-Apr-2025
     
    13. Place Of Completion
     
    Oslo, Norway
     
     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
     
     
     
     
    Smith & Nephew plc
     
     
    (Registrant)
     
     
     
     
     
     
    Date: April 28, 2025
    By:
    /s/ Helen Barraclough
     
     
    Helen Barraclough
     
     
    Company Secretary
    Get the next $SNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/21/25 10:40:08 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/14/25 8:13:22 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Smith & Nephew SNATS Inc.

      SD - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/9/25 11:07:04 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and

      5/14/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

      The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated:  Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 **  Superior functional gains: Patients treated with the

      5/7/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

      HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.   The Aurix product

      4/29/25 4:30:00 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care